Adenovirus armed with bispecific T cell engager

Inventors

CHAMPION, BRIAN ROBERT • BROMLEY, Alice Claire Noel • FREEDMAN, Joshua David • Fisher, Kerry David • Seymour, Leonard William

Assignees

Akamis Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12258417-B2

Patent

Publication Date

2025-03-25

Expiration Date


Abstract

A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engagers each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.

Core Innovation

The invention relates to an oncolytic adenovirus, Enadenotucirev (EnAd) or serotype 11 adenovirus (Ad11), engineered to encode two different bispecific T cell engagers. The virus encodes a tumour antigen-specific bispecific T cell engager comprising at least two binding domains Bd1 and Bd2, with at least one binding domain specific to a component of a T-cell receptor complex and at least one binding domain specific to a tumour antigen.

In parallel, the virus encodes a tumour stromal antigen-specific bispecific T cell engager comprising at least two binding domains Bd3 and Bd4, with at least one binding domain specific to a component of a T-cell receptor complex and at least one binding domain specific to a tumour stromal antigen. Both bispecific T cell engagers are encoded in position BY within a genetic arrangement defined by formula (I).

The arrangement includes defined components at B1, BA, B2, BX, BB, BY, and B3, wherein BX and BY comprise a restriction site and/or one or more transgenes, and B1, BA, B2, BB, and B3 comprise E1A, E1B or E1A-E1B, E2B-L1-L2-L3-E2A-L4, E3, L5, and E4, respectively. The disclosed system addresses immune recognition directed to both tumour and tumour stromal components through bispecific T cell engager activity encoded by the oncolytic adenovirus.

Claims Coverage

The document provides one independent claim covering an oncolytic adenovirus with a defined formula (I) genetic arrangement that encodes two bispecific T cell engagers positioned in BY, with the adenovirus limited to Enadenotucirev (EnAd) or serotype 11 adenovirus (Ad11).

Defined oncolytic adenovirus genetic arrangement encoding two bispecific T cell engagers

An oncolytic adenovirus comprising a sequence of formula (I) with defined components at B1, BA, B2, BX, BB, BY, and B3, wherein the adenovirus encodes a tumour antigen-specific bispecific T cell engager and a tumour stromal antigen-specific bispecific T cell engager.

Tumour antigen-specific bispecific T cell engager with TCR-component binding and tumour-antigen binding

A tumour antigen-specific bispecific T cell Engager comprising at least two binding domains Bd1 and Bd2, wherein at least one binding domain is specific to a component of a T-cell receptor complex (TCR) and at least one binding domain is specific to a tumour antigen.

Tumour stromal antigen-specific bispecific T cell engager with TCR-component binding and tumour-stromal-antigen binding

A tumour stromal antigen-specific bispecific T cell Engager comprising at least two binding domains Bd3 and Bd4, wherein at least one binding domain is specific to a component of a T-cell receptor complex (TCR) and at least one binding domain is specific to a tumour stromal antigen.

Both bispecific T cell engagers encoded in position BY

Both bispecific T cell Engagers are encoded in position BY.

Adenovirus is Enadenotucirev or serotype 11 adenovirus

The adenovirus is Enadenotucirev (EnAd) or serotype 11 adenovirus (Ad11).

Overall, the claim coverage is anchored by a defined formula (I) genetic element arrangement in which both a tumour antigen-specific bispecific T cell engager and a tumour stromal antigen-specific bispecific T cell engager are encoded in position BY, with specified TCR-complex binding and tumour/tumour-stromal antigen binding, and with the adenovirus restricted to EnAd or Ad11.

Stated Advantages

Selective killing of EpCAM+ cells.

Activation of endogenous patient T cells despite immune suppression and PD-1-rich environments.

T-cell activation driven by supernatants from EnAd-infected cells.

Improved lysis of relatively resistant SKOV3 targets.

Piggyback delivery of BiTEs via adenoviral tumor selectivity.

Local BiTE production and secretion after infection/lysis.

Reduced off-target risk via short BiTE half-life.

Improved targeting of tumor stroma and immune-suppressive microenvironment.

Potential synergy with checkpoint inhibition.

Documented Applications

In vitro, ex vivo, and in vivo evaluation of oncolytic adenoviruses engineered to express EpCAM- or FAP-specific bispecific T cell engagers.

Functional activity in immunosuppressive malignant ascites/peritoneal malignant exudate and pleural effusion fluids, including activation of endogenous patient T cells and cytokine/residual tumour/cell depletion readouts.

Use in tissue slice models (prostate tissue slice cultures).

Platform extension to other BiTE targets (FAP), multi-target/co-expressing viruses, and immune-modulatory transgene arming.

Treatment of cancer, including solid tumors and metastasis, using the described oncolytic adenovirus platform encoding bispecific T cell engagers.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.